Scientific Industries, Inc. is engaged in the design, manufacture, and marketing of standard benchtop laboratory equipment and bioprocessing systems for research and industrial applications. The company, incorporated in 1954 and headquartered in Bohemia, New York, serves universities, pharmaceutical companies, pharmacies, national laboratories, medical device manufacturers, and other research focused industries.

Revenue is derived from the sale of benchtop laboratory equipment such as pharmacy and laboratory balances, scales, force gauges, automated pill counters, and moisture analyzers under the Torbal® and VIVID® brands, as well as bioprocessing products including smart sensor integrated systems for biomass monitoring, automated feeding, and pH and dissolved oxygen measurement. The company sells these products through a direct sales force, a network of distributors, and online channels.

The company operates through the following segments:

• Benchtop Laboratory Equipment and Weighing Instruments includes pharmacy and laboratory balances, scales, force gauges, automated pill counters, moisture analyzers, and related products sold through the Torbal® division and the VIVID® brand, primarily via distributors, online channels, and direct sales.

• Bioprocessing Systems encompasses the design, development, manufacture, and marketing of smart sensor integrated products such as the Cell Growth Quantifier, Liquid Injection System, coaster systems, flow through cells, Multi Parameter Sensor, and Dissolved Oxygen sensor pills, marketed under the DOTS brand platform and sold mainly through a direct sales force and a network of distributors.

Scientific Industries, Inc. competes in a fragmented market where many rivals are larger and possess greater financial, production, and marketing resources.

The company’s customers consist of universities, pharmaceutical companies, pharmacies, national laboratories, medical device manufacturers, and other industries conducting laboratory scale research. A single customer accounted for 31% of consolidated net revenues in 2025 and 23% in 2024, primarily purchasing VIVID® automated pill counters.